Ferrier-Rembert Audrey, Drillien Robert, Tournier Jean-Nicolas, Garin Daniel, Crance Jean-Marc
Unité de Virologie, Centre de Recherches du Service de Santé des Armées (CRSSA) Emile Pardé, F-38702 Grenoble, France.
Vaccine. 2007 Jun 15;25(25):4809-17. doi: 10.1016/j.vaccine.2007.04.011. Epub 2007 Apr 24.
The intranasal infection of mice with cowpox virus (CPXV) has been evaluated as a model for smallpox infection in man. Administration of a lethal dose of CPXV allowed time for development of T-cell responses but antibodies could not be detected before death occurred. In contrast, infection with a sublethal dose was associated with an early T-cell response followed by neutralising antibodies which correlated with virus clearance. Comparison of two first generation smallpox vaccines revealed no significant differences in terms of immunogenicity, protection and post-challenge virus clearance. These studies show that the CPXV/mouse model is valuable for the initial assessment of smallpox vaccines.
用牛痘病毒（CPXV）对小鼠进行鼻内感染已被评估为人类天花感染的一种模型。给予致死剂量的CPXV能让T细胞反应得以发展，但在死亡发生前无法检测到抗体。相比之下，用亚致死剂量感染则与早期T细胞反应相关，随后出现中和抗体，这与病毒清除相关。对两种第一代天花疫苗的比较显示，在免疫原性、保护作用和攻毒后病毒清除方面没有显著差异。这些研究表明，CPXV/小鼠模型对于天花疫苗的初步评估具有重要价值。
